Bupropion for the treatment of methamphetamine dependence
Bupropion for the treatment of methamphetamine dependence
复制标题
DOI：
10.1038/sj.npp.1301481
复制
发表时间：
2008-04-01
影响因子：
7.6
通讯作者：
Weis, Dennis
中科院分区：
文献类型：
--
作者：
Elkashef, Ahmed M.;Rawson, Richard A.;Weis, Dennis
与安慰剂相比，安非他酮在甲基苯丙胺依赖患者中增加戒断周数的疗效进行了测试。这是一项双盲安慰剂对照研究，治疗12周，随访30天。位于密西西比西部的五家药物滥用治疗门诊诊所参与了这项研究。151名DSM-IV诊断为甲基苯丙胺依赖的寻求治疗者同意并入组。72名参与者被随机分配到安慰剂组，79名参与者被随机分配到缓释安非他酮组，150 mg，每日两次。患者被要求每周三次来诊所进行评估，尿液药物筛查和90分钟的团体心理治疗。主要结果是无甲基苯丙胺周参与者比例的变化。次要结局包括：尿定量甲基苯丙胺，甲基苯丙胺使用的自我报告，平衡因素和共病状况的亚组分析，成瘾严重程度，渴望，HIV风险行为和其他物质的使用。广义估计方程回归分析显示，总体而言，安非他酮组和安慰剂组在12周治疗期间未使用周的概率差异无统计学显著性（p = 0.09）。使用混合模型回归，以允许调整基线因素，除了那些测量（网站，性别，基线使用水平，抑郁症状的水平）。亚组分析显示，与安慰剂相比，安非他酮在基线时甲基苯丙胺使用水平较低的男性患者中具有显著效果（p
Bupropion was tested for efficacy in increasing weeks of abstinence in methamphetamine-dependent patients, compared to placebo. This was a double-blind placebo-controlled study, with 12 weeks of treatment and a 30-day follow-up. Five outpatient substance abuse treatment clinics located west of the Mississippi participated in the study. One hundred and fifty-one treatment-seekers with DSM-IV diagnosis of methamphetamine dependence were consented and enrolled. Seventy-two participants were randomized to placebo and 79 to sustained-release bupropion 150 mg twice daily. Patients were asked to come to the clinic three times per week for assessments, urine drug screens, and 90-min group psychotherapy. The primary outcome was the change in proportion of participants having a methamphetamine-free week. Secondary outcomes included: urine for quantitative methamphetamine, self-report of methamphetamine use, subgroup analyses of balancing factors and comorbid conditions, addiction severity, craving, risk behaviors for HIV, and use of other substances. The generalized estimating equation regression analysis showed that, overall, the difference between bupropion and placebo groups in the probability of a non-use week over the 12-week treatment period was not statistically significant (p = 0.09). Mixed model regression was used to allow adjustment for baseline factors in addition to those measured (site, gender, level of baseline use, and level of symptoms of depression). This subgroup analysis showed that bupropion had a significant effect compared to placebo, among male patients who had a lower level of methamphetamine use at baseline (p